Publikationen von Michael Werner Sereda
Alle Typen
Zeitschriftenartikel (44)
1.
Zeitschriftenartikel
Intraepidermal nerve fibre density as biomarker in Charcot–Marie–Tooth disease type 1A. Brain Communications (2020)
2.
Zeitschriftenartikel
39 (28), S. 5606 - 5626 (2019)
Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy. The Journal of Neuroscience 3.
Zeitschriftenartikel
10 (1), 1840 (2019)
NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies. Nature Communications 4.
Zeitschriftenartikel
14 (1), e0209752 (2019)
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One 5.
Zeitschriftenartikel
9 (1), 3025 (2018)
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature Communications 6.
Zeitschriftenartikel
88 (11), S. 941 - 952 (2017)
Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery & Psychiatry 7.
Zeitschriftenartikel
6, e23332 (2017)
Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy. eLife 8.
Zeitschriftenartikel
8, 17 (2017)
Rho kinase inhibition with Fasudil in SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis - symptomatic treatment potential after diesease onset. Frontiers in Pharmacology 9.
Zeitschriftenartikel
Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair. Nature Neuroscience, 10.1038/nn.4321 (2016)
10.
Zeitschriftenartikel
95 (11), S. 145 - 157 (2016)
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiology of Disease 11.
Zeitschriftenartikel
18 (5), S. 443 - 451 (2015)
The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy. Genetics in Medicine 12.
Zeitschriftenartikel
4, 53 (2015)
A brief review of recent Charcot-Marie-Tooth research and priorities. Faculty of 1000 Research 13.
Zeitschriftenartikel
2 (8), S. 787 - 796 (2015)
Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease. Annals of clinical and translational neurology 14.
Zeitschriftenartikel
64 (1), S. 155 - 174 (2015)
Proteolipid protein modulates preservation of peripheral axons and premature death when myelin protein zero is lacking. Glia 15.
Zeitschriftenartikel
9 (1), 201 (2014)
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet Journal of Rare Diseases 16.
Zeitschriftenartikel
34 (44), S. 14506 - 14516 (2014)
Annexin A2 regulates TRPA1-dependent nociception. Journal of Neuroscience 17.
Zeitschriftenartikel
20 (9), S. 1055 - 1061 (2014)
Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nature Medicine 18.
Zeitschriftenartikel
94, S. 533 - 546 (2014)
Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model. American Journal of Human Genetics 19.
Zeitschriftenartikel
62 (2), S. 217 - 232 (2014)
Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. GLIA 20.
Zeitschriftenartikel
24, S. 1003 - 1017 (2014)
Selected items from the Charcot-Marie-Tooth (CMT) neuropathy score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders